argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of "Buy" by Brokerages

Shares of argenx SE (NASDAQ:ARGX - Get Free Report) have been assigned an average recommendation of "Buy" from the twenty-three ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, twenty have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $698.11.

A number of research firms recently commented on ARGX. HC Wainwright reaffirmed a "buy" rating and set a $720.00 price target on shares of argenx in a research report on Tuesday, April 8th. Oppenheimer raised their price target on shares of argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. JMP Securities set a $699.00 price target on shares of argenx in a research report on Wednesday, May 14th. Robert W. Baird raised shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target on the stock in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company raised their price target on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th.

argenx Stock Down 1.3%

Shares of NASDAQ ARGX traded down $7.84 during mid-day trading on Thursday, reaching $579.77. 339,403 shares of the company were exchanged, compared to its average volume of 325,549. The company's 50-day simple moving average is $588.46 and its 200-day simple moving average is $612.85. The stock has a market capitalization of $35.40 billion, a P/E ratio of -658.83 and a beta of 0.57. argenx has a twelve month low of $359.37 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. As a group, equities research analysts expect that argenx will post 3.13 EPS for the current year.

Institutional Investors Weigh In On argenx

Several hedge funds and other institutional investors have recently made changes to their positions in ARGX. FMR LLC grew its holdings in shares of argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after purchasing an additional 824,750 shares during the last quarter. Millennium Management LLC grew its holdings in shares of argenx by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company's stock valued at $158,977,000 after purchasing an additional 204,180 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of argenx during the 4th quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC grew its holdings in shares of argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock valued at $89,391,000 after purchasing an additional 143,834 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of argenx by 53,684.9% during the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock valued at $802,200,000 after purchasing an additional 135,286 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.